CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the
Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026,
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 Company to host investor call on March 25, 2026, at 8:30 a.m. Eastern time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 24, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early
– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and acute liver failure (ALF) associated with AAV gene therapy in
– Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration and its impact in Duchenne CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product
- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2026-- Sarepta Therapeutics, Inc.